The U.S. is making strides in addressing the drug and device supply chain vulnerabilities revealed by the COVID-19 pandemic, but there’s still a lot of work to do to reduce dependance on sole source suppliers and foreign manufacturing, according to a new Health and Human Services (HHS) report.
SK Bioscience Ltd. is developing a vaccine intended to simultaneously immunize people against the flu and COVID-19. It is the first vaccine of its type to be developed in South Korea and will use the technology from Skycellflu, a cell-cultivated influenza vaccine developed by the Seongnam-si, South Korea-based company.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beartooth, Cantex, Cassiopea, Clover, CSL, FSD, Hitgen, Mitsubishi Tanabe, Privo, Pulmatrix, Sanofi, Seqirus, Sunshine, TFF and Vibliome.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arrowhead, Biocryst, Centessa, Innovent, Insilico, Jacobio, Lysogene, Point, Regulus, Sarepta, Simcere, TFF, Trevi, Vaxcyte.
The deadly SARS-CoV-2 virus that has cost nearly 6 million lives worldwide and disrupted global economies has brought the biopharma industry $82 billion in sales revenue since the start of the pandemic, with guidance for another $88 billion this year.
RSS
